Evidence map›Paper›PMID 33407527›Full record

ArticleJournal of nanobiotechnology2021

Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma.

Qiangqiang Zhao, Xiaoying Sun, Bin Wu, Yinghui Shang, Xueyuan Huang, Hang Dong, Haiting Liu, Wansong Chen, Rong Gui, Jian Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Current issues in molecular biology · 2025
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Qiangqiang ZhaoDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Xiaoying SunSchool of Nursing, Medical College, Soochow University, Suzhou, 215006, People's Republic of China.
Bin WuDepartment of Transfusion Medicine, Tongji Medical College, Wuhan Hospital of Traditional Chinese and Western Medicine, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Yinghui ShangDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Xueyuan HuangDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Hang DongDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Haiting LiuDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
Wansong ChenCollege of Chemistry and Chemical Engineering, Central South University, Changsha, 410083, People's Republic of China.
Rong GuiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. zndxgr@163.com.
Jian LiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China. lj168301018@csu.edu.cn.
Central South University · CNThird Xiangya Hospital · CNHuazhong University of Science and Technology · CNSoochow University · CN

Funding

Fundamental Research Funds for Central Universities of the Central South University No. 2019zzts366National Natural Science Foundation of China No. 8157120841
6 · The paper itself

Abstract

backgroundNon-Hodgkin's lymphoma (NHL) possesses great heterogeneity in cytogenetics, immunophenotype and clinical features, and chemotherapy currently serves as the main treatment modality. Although employing monoclonal antibody targeted drugs has significantly improved its overall efficacy, various patients continue to suffer from drug resistance or recurrence. Chinese medicine has long been used in the treatment of malignant tumors. Therefore, we constructed a low pH value sensitivity drug delivery system based on the cancer cell membrane modified mesoporous silica nanoparticles loaded with traditional Chinese medicine, which can reduce systemic toxicity and improve the therapeutic effect for the targeted drug delivery of tumor cells.

resultsAccordingly, this study put forward the construction of a nano-platform based on mesoporous silica nanoparticles (MSNs) loaded with the traditional Chinese medicine isoimperatorin (ISOIM), which was camouflaged by the cancer cell membrane (CCM) called CCM@MSNs-ISOIM. The proposed nano-platform has characteristics of immune escape, anti-phagocytosis, high drug loading rate, low pH value sensitivity, good biocompatibility and active targeting of the tumor site, blocking the lymphoma cell cycle and promoting mitochondrial-mediated apoptosis.

conclusionsFurthermore, this study provides a theoretical basis in finding novel clinical treatments for lymphoma.

Indexed as

Cell MembraneAnimalsAntineoplastic AgentsApoptosisBiocompatible MaterialsCell ProliferationDisease Models, AnimalDrug CarriersDrug Delivery SystemsFurocoumarinsHumansLymphomaMedicine, Chinese TraditionalMiceMice, NudeNanoparticlesAntineoplastic AgentsBiocompatible MaterialsDrug CarriersFurocoumarinsisoimperatorinReactive Oxygen SpeciesSilicon DioxideApoptosisCancer cell membraneIsoimperatorinLymphomMesoporous silica nanoparticles

Identifiers

PMID33407527
PMCPMC7789287
OpenAlexW3120339516

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.